# A Study of SRSD216 in Patients With Elevated Lipoprotein (a)

> **NCT07172646** · PHASE1,PHASE2 · RECRUITING · sponsor: **Sirius Therapeutics Co., Ltd.** · enrollment: 84 (estimated)

## Conditions studied

- Hyperlipoproteinemia (a)

## Interventions

- **DRUG:** SRSD216 injection
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07172646
- **Lead sponsor:** Sirius Therapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-07
- **Primary completion:** 2026-05
- **Final completion:** 2027-04
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2026-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07172646

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07172646, "A Study of SRSD216 in Patients With Elevated Lipoprotein (a)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07172646. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*